Last reviewed · How we verify
HPV Vaccine Communication ECHO for Primary Care Clinics
NA trial testing Project ECHO in Human Papillomavirus Vaccines in 30 participants. Completed in 30 April 2025.
| Lead sponsor | Milton S. Hershey Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 30 |
| Start date | 1 May 2021 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across United States |
Milton S. Hershey Medical Center
18 and older, any sex, with Human Papillomavirus Vaccines or Adolescent Health Services. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Coverage change from baseline to 12 months in HPV vaccine initiation (≥1 dose), among 11- to 14- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 3189 | ± 2 |
| HPV ECHO+ | 3833 | ± 2 |
| Control | 4260 | ± 2 |
Coverage change from baseline to 3 months in HPV vaccine initiation (≥1 dose), among 11- to 14- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 2483 | |
| HPV ECHO+ | 1759 | |
| Control | 4083 |
Coverage change from baseline to 6 months in HPV vaccine initiation (≥1 dose), among 11- to 14- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 2584 | |
| HPV ECHO+ | 1831 | |
| Control | 4177 |
Coverage change from baseline to 9 months in HPV vaccine initiation (≥1 dose), among 11- to 14- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 2744 | |
| HPV ECHO+ | 1888 | |
| Control | 4102 |
Coverage change from baseline to 3 months in HPV vaccine completion (according to the Advisory Committee on Immunization Practices (ACIP) guidelines), among 11- to 14- year-old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1517 | |
| HPV ECHO+ | 1063 | |
| Control | 3075 |
Coverage change from baseline to 6 months in HPV vaccine completion (according to the Advisory Committee on Immunization Practices (ACIP) guidelines), among 11- to 14- year-old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1655 | |
| HPV ECHO+ | 1156 | |
| Control | 3249 |
Coverage change from baseline to 9 months in HPV vaccine completion (according to the Advisory Committee on Immunization Practices (ACIP) guidelines), among 11- to 14- year-old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1817 | |
| HPV ECHO+ | 1232 | |
| Control | 3180 |
Coverage change from baseline to 12 months in HPV vaccine completion (according to the Advisory Committee on Immunization Practices (ACIP) guidelines), among 11- to 14- year-old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1984 | |
| HPV ECHO+ | 1946 | |
| Control | 3432 |
Coverage change from baseline to 3 months in HPV vaccine initiation (≥1 dose), among 15- to 17- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1965 | |
| HPV ECHO+ | 1801 | |
| Control | 3182 |
Coverage change from baseline to 6 months in HPV vaccine initiation (≥1 dose), among 15- to 17- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1976 | |
| HPV ECHO+ | 1805 | |
| Control | 3158 |
Coverage change from baseline to 9 months in HPV vaccine initiation (≥1 dose), among 15- to 17- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 1997 | |
| HPV ECHO+ | 1812 | |
| Control | 3185 |
Coverage change from baseline to 12 months in HPV vaccine initiation (≥1 dose), among 15- to 17- year old patients, as measured by clinics' records
| Group | Value | 95% CI |
|---|---|---|
| HPV ECHO | 2397 | |
| HPV ECHO+ | 3684 | |
| Control | 3176 |
The safe, highly-effective human papillomavirus (HPV) vaccine remains underused in the US; only 51% of 13- to 17-year-old girls and boys were up-to-date by 2018. The Announcement Approach Training is effective in increasing HPV vaccine uptake during the clinic visit by training providers to make strong vaccine recommendations and answer parents' common questions. Systems communication like recall notifications also improve vaccination by reducing missed clinical opportunities. Although never tested to support HPV vaccination, the ECHO (Extension for Community Healthcare Outcomes) Model is a proven implementation strategy to promote capacity exchange between health care experts at academic centers and primary care providers at the front line of rural community health care. The trial will test the effectiveness of two ECHO-delivered HPV vaccination communication interventions versus control: HPV ECHO will provide Announcement Approach training, and HPV ECHO+ will provide training plus recall notices to communicate with parents who initially decline vaccination.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Trials testing the same drug.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04587167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing